



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Appendix 4C Quarterly Cash Flow Report 31 March 2020

Sydney, Australia & Auckland, New Zealand, 29 April 2020 – Living Cell Technologies Limited today released its cash flow report for the quarter ended 31 March 2020. The Appendix 4C is attached. The company ended the quarter with a cash balance of \$3,633,042 compared to \$3,477,874 in the previous quarter. The cash balance has been boosted by the R&D rebate from Callaghan Innovation, tax credit from the Inland Revenue Department and reduced expenditure at the University of Auckland because of its closure to contain the spread of COVID-19.

Net operating cash flow in the quarter was \$140,454 compared to \$(967,063) in the previous quarter. Receipts from grants and tax incentives were \$648,733 (previous quarter \$107,279).

Operating payments were \$548,032 compared to \$1,108,143 in the previous quarter.

CEO, Dr Ken Taylor says that despite the global impact of COVID-19 and the Level 4 restrictions in New Zealand, business continues for LCT.

“We maintain contacts with the University of Auckland with regards to revised timelines for the obesity and migraine projects, which are dependent on the date the University reopens its laboratories.

“Our activities to pursue the next step for NTCELL® for Parkinson’s disease are also ongoing.”

LCT management work from home during the COVID-19 restrictions. Suppliers have been contacted to obtain relief for payments while LCT’s offices remain closed.

“In all cases suppliers have been very accommodating,” says Dr Taylor. “All the organisations we’ve talked to have understood the need to continue core activities and pause other services. Our objective is to preserve our cash runway as much as possible.”

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

<p>At the Company: Ken Taylor Chief Executive Mobile: +64 21 796 000 ktaylor@lctglobal.com</p>	<p>Media Contact: Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz</p>
--	--

About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

As well as NTCELL, LCT is also advancing research collaborations with the University of Auckland to identify products that are candidates for out licensing to global pharmaceutical companies. Projects that have been initiated target obesity and migraine where the lead product candidates utilise patented novel peptide synthetic chemistry technology.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.